Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Germinal Center B-cell Type (GCB) Clear all

Terminated Phase 1 Interventional Results available

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

NCT04933617

View directory record Official record

Conditions: Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
Interventions: Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP); Biological · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 8, 2024 · Synced May 21, 2026, 10:11 PM EDT

Active, not recruiting Phase 3 Interventional

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772

View directory record Official record

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 28 more

Source: ClinicalTrials.gov public record

Updated Mar 30, 2026 · Synced May 21, 2026, 10:11 PM EDT

Recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

NCT06667687

View directory record Official record

Conditions: Non-Hodgkin's Lymphoma
Interventions: ABBV-291; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Huntersville, North Carolina • Eugene, Oregon • Austin, Texas + 2 more

Source: ClinicalTrials.gov public record

Updated Jan 25, 2026 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

NCT00931918

View directory record Official record

Conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 70
States / cities: Beverly Hills, California • Fountain Valley, California • Fullerton, California + 58 more

Source: ClinicalTrials.gov public record

Updated Jan 10, 2017 · Synced May 21, 2026, 10:11 PM EDT

Terminated Phase 1 Interventional

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

NCT03558750

View directory record Official record

Conditions: Recurrent Central Nervous System Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Central Nervous System Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Nivolumab, Rituximab, Lenalidomide; Biological · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 19 Years and older

Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Source: ClinicalTrials.gov public record

Updated Apr 24, 2019 · Synced May 21, 2026, 10:11 PM EDT

Recruiting Phase 1 Interventional

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

NCT05780034

View directory record Official record

Conditions: Relapsed/Refractory B-cell Malignancies
Interventions: AC676; Drug
Lead sponsor: Accutar Biotechnology Inc; Industry
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • Sarasota, Florida • Chapel Hill, North Carolina + 6 more

Source: ClinicalTrials.gov public record

Updated Oct 1, 2025 · Synced May 21, 2026, 10:11 PM EDT